Voteopolis | 116th-congress-H.R.5882 Bill DashBoard

| | Petition Blog | << < > >>

Introduced in House	Passed House	Introduced in Senate	Passed Senate	To President	Became Law
02/12/2020

GENE Therapy Payment Act

Date	Version	PDF	TXT
01/01/2111		Open
02/12/2020	Introduced in House	Open

2 1 to 12 of 2

Name	From	Date	Type
Kurt Schrader	D-OR	02/12/2020	Sponsor
David Schweikert	R-AZ	02/12/2020	Cosponsor
Markwayne Mullin	R-OK	02/12/2020	Cosponsor
Roger Marshall	R-KS	02/12/2020	Cosponsor
Mike Kelly	R-PA	02/12/2020	Cosponsor
Jason Crow	D-CO	02/12/2020	Cosponsor
Ami Bera	D-CA	02/12/2020	Cosponsor

2 1 to 12 of 7

Date	Branch	Action
02/12/2020	President	Referred to the House Committee on Energy and Commerce.Action By: House of Representatives
02/12/2020	President	Introduced in HouseAction By: House of Representatives

2 1 to 12 of 2

Summary
There is one summary for H.R.5882. View summaries Shown Here:Introduced in House (02/12/2020) Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
Shown Here:Introduced in House (02/12/2020) Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

Summary

There is one summary for H.R.5882. View summaries Shown Here:Introduced in House (02/12/2020) Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

Shown Here:Introduced in House (02/12/2020) Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.

2 1 to 12 of 2

Congress - Bill Number	Major Title

2 1 to 12 of 0

Branch	Vote Date	Yes	No	Not Voting

2 1 to 12 of 0

Wiki

Bill TEXT Points.
This Bill has been listed with the following Subjects from Texts:
Appropriations
(10)AppropriationsFor fiscal year 2020 and each fiscal year thereafter, there are appropriated to the Secretary $5,000,000 for the purpose of carrying out this subsection

Commerce
Schweikert) introduced the following bill; which was referred to the Committee on Energy and CommerceA BILLTo amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes

Congress
(7)Assessments and report to Congress(A)Assessments(i)In generalNot later than 180 days after the end of each assessment period of any risk-sharing value-based payment agreement for a State approved under this subsection, the Secretary shall conduct an evaluation of such agreement which shall include an evaluation by the Chief Actuary to determine whether program spending under the risk-sharing value-based payment agreement aligned with the projections for the agreement made under paragraph (2)(

Death
(B)DeathIn the case of an individual described in subparagraph (A) who dies during the period described in such subparagraph, the State plan shall not be liable for any remaining payment for the unit of the covered outpatient drug administered to the individual which is owed under the agreement described in such subparagraph

End Bill TEXT Points.

Date	Bill	Major Title

2 1 to 12 of 0

Committee Name

2 0 to 12 of 0

Subject	Type

2 1 to 12 of 0

Top

2 1 to 12 of 0